ubjects. some of the subjects showed a
second peak during distribution in some occasions but not in other
occasions. Not sure how to handle all these visibilities in my data and get
the good fit of absorption phase.
Any suggestions would be appreciated.
Thanks!
Best,
--
Xu, Claire
Ph.D Candidate
> predict Cmax well, such as more complex absorption features. I think we
> lack info to comment on that.
>
> HTH, Klaas
>
>
> On 10 jul. 2012, at 23:56, "Lavigne, Jean"
> wrote:
>
> > KA=THETA(1)*EXP(BOVKA)
>
>
--
Xu, Claire
Ph.D Candidate
Division of
PF1*EXP(ETA(F1)+BOVF1)
> where POPF1 would typically be set to 1 (unless you had a better idea of
> what the actual mean bioavailability of oral doses was) and ETA(F1) is the
> ETA for BSV of F1.
>
> Nick
>
>
> On 11/07/2012 7:16 a.m., Xu, Claire wrote:
>
>> Hi Kla
See below:
>
>
> On 11/07/2012 9:45 p.m., Xu, Claire wrote:
>
>> Hi Nick,
>> Thank you a lot for clarifying how to incorporate BOV in the model.
>> I tested BOV on F1 with the same option as well as variable BOVs on F1
>> from different occasions. But either of them im
ments or suggestions ?
Thanks a lot!
Best,
--
Xu, Claire
Ph.D Candidate
Division of Clinical Pharmacology, Wishard Hospital
Indiana University School of Medicine
1001 West 10th Street, Myers W7122
Indianapolis, IN 46202
T - 317/7558242
University
>
> Box 591
>
> 75124 Uppsala
>
> ** **
>
> Phone: +46 18 4714105
>
> Fax + 46 18 4714003
>
> ** **
>
> *From:* owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com]
> *On Behalf Of *Xu, Claire
> *Sent:* 23 July
HEN
> BOVKA=ETA(7)
> ENDIF
>
>
>
>
>
> IF (MIXNUM==1) THEN; pop1
> KA=THETA(3)
> ELSE
> KA=THETA(4)*EXP(ETA(8)+BOVKA); pop 2
> ENDIF
>
> --
> *From:* owner-nmus...@globomaxnm.com [owner-nmus...@globomaxnm.com] on
&g
